Skip to content

R&D at other companies

Baxter International logo
Baxter InternationalBAX
$139M-0.7%
PTH
Pelthos Therapeutics Inc.PTHS
$186K-4.1%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.68M+38.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$126.64M+13.6%
RFL
Rafael Holdings, Inc.RFL
$4.85M+61.6%
Opko Health logo
Opko HealthOPK
$29.2M-5.3%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's R&D?
Cumberland Pharmaceuticals (CPIX) reported R&D of $1.46M in Q1 2026.
How has Cumberland Pharmaceuticals's R&D changed year-over-year?
Cumberland Pharmaceuticals's R&D increased by 12.6% year-over-year, from $1.3M to $1.46M.
What is the long-term trend for Cumberland Pharmaceuticals's R&D?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's R&D has grown at a -0.5% compound annual growth rate (CAGR), from $5.68M to $5.57M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.